1.
Proc (Bayl Univ Med Cent)
; 30(1): 71-73, 2017 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28127140
RESUMO
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.